Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Arrowhead Pharmaceuticals, Inc. - Common Stock (NQ:ARWR)

10.86 UNCHANGED
Streaming Delayed Price Updated: 2:55 PM EDT, Apr 4, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Arrowhead Pharmaceuticals, Inc. - Common Stock

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Arrowhead Pharmaceuticals’ Proprietary Pulmonary TRiM™ Platform Achieves High Levels of Target Gene Knockdown and Long Duration of Effect
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Arrowhead Pharmaceuticals to Webcast Fiscal 2023 Second Quarter Results
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Is Arrowhead Pharmaceuticals a Buy Now?
The clinical-stage drug developer is attracting a lot of positive attention from investment bank analysts. 
Via The Motley Fool
Expert Ratings for Arrowhead Pharma
Via Benzinga
Analyst Ratings for Arrowhead Pharma
Via Benzinga
Arrowhead Pharmaceuticals's Return On Capital Employed Overview
Via Benzinga
Earnings Outlook For Arrowhead Pharmaceuticals
Via Benzinga
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) Making Surprising Moves in Thursday Session
Via Investor Brand Network
Analyst Upgrades Arrowhead Pharma Citing 'Attractive Risk/Reward'
SVB Securities upgraded Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) to Outperform from Market Perform on attractive risk-reward following shares' underperformance relative to larger cap oligo therapy... 
Via Benzinga
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) Highlighted for Surprising Price Action
Via Investor Brand Network
Arrowhead Pharmaceuticals to Host R&D Day on Pipeline of RNAi Therapeutics
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
2 Biotech Stocks That Could Soar by 130% and 92%, According to Wall Street
Arrowhead Pharmaceuticals and Seres Therapeutics are screaming buys, according to some Wall Street analysts. 
Via The Motley Fool
Why Panbela Therapeutics Shares Are Trading Higher By Around 25%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Gainers TESSCO Technologies Incorporated (NASDAQ: TESS) shares jumped 86.8% to $8.78 as it agreed to be acquired by entities affiliated with Lee Equity Partners and Twin Point Capital for $9.00 in... 
Via Benzinga
First Patient Treated in Alpha-1 Antitrypsin Deficiency Liver Disease Phase 3 Study Triggering $40 Million Milestone Payment from Takeda to Arrowhead
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For April 12, 2023
Via Benzinga
Arrowhead Pharmaceuticals Announces $30 Million Milestone Payment from GSK
From Arrowhead Pharmaceuticals Inc.
Via Business Wire
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Want Diversified Upside in Biotechnology? Check out LABU
Watch the Direxion Daily S&P 500 Biotech Bull 3X Shares (NYSEARCA: LABU) if you want a speculative play in the biotechnology industry with amplified volatility. 
Via MarketBeat
Topics ETFs Stocks
Exposures US Equities
Benzinga's Top Ratings Upgrades, Downgrades For March 21, 2023
Via Benzinga
Arrowhead Receives FDA Fast Track Designation for ARO-APOC3
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Arrowhead Pharmaceuticals to Present at 43rd Annual Cowen Health Care Conference
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Arrowhead Announces Interim Results from Ongoing Phase 1/2 Study of ARO-C3 for Treatment of Complement Mediated Diseases
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
JNJ Terminates NASH Program Pact With Arrowhead Pharmaceuticals
Via Benzinga
Arrowhead Pharmaceuticals Gains Full Rights to NASH Candidate ARO-PNPLA3 with Promising Phase 1 Results
From Arrowhead Pharmaceuticals Inc.
Via Business Wire
Arrowhead Pharmaceuticals Reports Fiscal 2023 First Quarter Results
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Why Omeros Are Trading Higher By 32%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers Secoo Holding Limited (NASDAQ: SECO) jumped 156% to $4.3600. Arqit Quantum Inc. (NASDAQ: ARQQ) gained 41.5% to $3.54. 
Via Benzinga
Energizer, Children's Place And Other Big Stocks Moving Lower On Monday
U.S. stocks traded lower, with the Dow Jones dropping over 150 points on Monday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
Earnings Scheduled For February 6, 2023
Companies Reporting Before The Bell • Cummins (NYSE:CMI) is projected to report quarterly earnings at $4.56 per share on revenue of $7.21 billion. 
Via Benzinga
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-MMP7 for Treatment of Idiopathic Pulmonary Fibrosis
From Arrowhead Pharmaceuticals Inc.
Via Business Wire
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.